GI View FDA clearance, $129k Boston Scientific stock transaction & more – 5 recent GI/endoscopy key notes

Here are five recent updates on gastroenterology and endoscopy companies.

Advertisement

Boston Scientific director Ernest Mario sold 10,000 shares of company stock at an average of $12.96 per share. The total transaction value was $129,600, according to a WKRB News & Analysis report.

Carnegie Hill Endoscopy in New York will hold an open house to Can gastroenterologists create a sustainable future in uncertain times?FUSE endoscopy technology from EndoChoice.

CMS issued its final payment decision for Exact Sciences’ FDA-approved noninvasive stool DNA colorectal cancer screening test Cologuard. CMS will reimburse providers $502 per test.

The FDA granted the Aer-O-Scope Colonoscope System from GI View 510(k) clearance.

Sanovas, a company focused on the development of minimally invasive diagnostics, has received recognition from Frost & Sullivan for its MicroCam Technology Platform. Sanovas will accept the “New Product Innovation Leadership in Endoscopic Imaging” award on Dec. 2 in Toronto, Canada.

If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.

More articles on gastroenterology:
ASGE, ACG update GI procedure quality indicators
4 gastroenterologists on the move
Can gastroenterologists create a sustainable future in uncertain times?

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.